Medical devices are an innovative, essential, and rapidly evolving component of healthcare technology and delivery. This unique conference will provide an overview of how emerging technologies and commercialization strategies are critically contributing to important medical device advances, resulting in dramatic changes in healthcare and the industry’s ability to address critical unmet medical needs. MedInnovation Boston 2018 will begin with a plenary session to set the tone for discussion and action, followed by concurrent tracks to explore the strategy and tactics of emerging products to market.

The morning session will celebrate successes in medical device design and commercialization through keynote speakers and organizational case studies highlighting advances in technologies and approaches. The afternoon session will feature two speaker tracks for a more intimate discussion with organizational and technology leaders who are making important strides in advancing technologies and getting life-changing devices to the clinic.

MedInnovation Boston 2018 will provide an intimate forum for the exchange of ideas and strategies for the successful commercialization of new medical devices and technologies that will dramatically improve healthcare and provide an opportunity to network with leaders and colleagues in the field. You will hear stories of success and the challenges along the way to commercialization, as these leaders share their steps to building new modes of patient care, pioneering novel funding strategies, and devising paths to the clinic that are working today — with ample Q&A and networking time.


Leading Technology Companies Review Opportunities to Create Paradigm-Shifting Products & Approaches

MC10, Inc., Lexington, MA
Benjamin Schlatka, Co-Founder, Senior Vice President, Medical Device & Life Sciences

Leveraging internal competencies to uncover opportunities in an adjacent space: Hear how MC10 used its revolutionary stretchable electronics to bring to market thin, flexible adhesive sensors with broad applications for biometric healthcare analytics. MC10 augmented the company’s novel technology with a complete end-to-end system with mobile interfaces, cloud storage, and analytical tools to create a high barrier to competitors. Mr. Schlatka’s passion for growing and leading science based businesses led him to co-found MC10 in 2008. His multidisciplinary expertise in both material science and electronics uniquely position him to lead MC10’s partnership activities and growth across its medical, consumer, and government segments.

Sterilis Medical, LLC, Boxborough, MA
Mike Ferris, Senior Vice President, Marketing

Identifying overlooked market niches in a commoditized world: Transforming a commoditized market space requires a close examination of the problem, identification of pain points, and demonstration of benefits. Sterilis revolutionized the disposal of medical waste by shifting the disposal approach and coming up with a much more economical, environmentally safe, and lower-risk solution. Mr. Ferris is a brand management professional with history of leading growth and profitability in highly competitive markets. He is a results-driven leader with broad-based marketing and global P&L expertise. He is experienced at devising and implementing marketing, product, and branding strategies, and identifying new customer opportunities.

Corvida Medical, Eagan, MN
John Slump, BBA, Co-Founder & CFO

Creating a competitive advantage by improving healthcare worker and patient safety: While safety for healthcare workers and patients is top of mind, product safety is frequently overlooked. When the sister of one of Corvida’s founders was diagnosed with cancer, they became aware that millions of healthcare workers were routinely exposed to toxic chemotherapeutic drugs. These workers also used preparation and delivery systems that led to repetitive motion injuries. Hear how Corvida approached the problem to reduce risk and increase safety. To fund Corvida, Mr. Slump has sourced over $30 million of equity and nondilutive capital, including private investments, federal NIH/NCI SBIR grants, state awards, and bank debt. Previously, he served as co-founder and CFO of TranslaCare, Inc., a health IT start-up.


Expanding Horizons for Medical Devices

Improving Lives — Wearables, Accessibility, and Competition from Consumer Products: Integrating Cross-Industry Technologies
Stuart Long, CEO, Infobionics, Inc. and Art Combs, MD, Chief Medical Officer, MC10, Inc.

Moderated by Geoffrey Gill, President Shimmer Americas, and Roger Begin, Program Manager, MDG Boston

Advances in computing power, algorithms, miniaturization, and manufacturing are facilitating the rapid creation of extraordinarily diverse and useful wearables and related devices that often include artificial intelligence and augmented reality. From continual monitoring of vital signs to instant diagnosis, healthcare providers are finding that patients are using these devices themselves to take more responsibility for their health and well-being. Key issues include risks/safety concerns for FDA regulated vs. non-regulated consumer devices — whose and what data should be trusted and acted upon?

Advancing Personalized Medicine — Genomics Show the Way: Genomics Expansion of Medical Device Markets
Nikoletta Sidiropoulos, MD, Inaugural Medical Director of Genomic Medicine in the Department of Pathology and Laboratory Medicine for the University of Vermont Health Network; Patrice Milos, PhD, President, CEO & Founder, Medley Genomics, Inc.; and Daniel E. Levy, MD, Director, a Heart Study, and Chief of Popular Sciences Branch, NHLBI

Moderated by Marnie Gilbert, PhD, Director of Programs, Personal Genetics Education Project

As individual genomics for patients enters the clinic, healthcare will evolve dramatically. This includes identifying risk profiles for earlier intervention, advances in individualized treatments in order to create truly personalized medicine, new tools for patient compliance, including those driven by artificial intelligence and augmented reality, and overall better tracking/monitoring of health. Medical devices will play a very large role — applications include comprehensive, computer-driven analysis of patient tissues, integrated electronic health records, and much more. Most critically, the data, devices, and online resources must be intelligently integrated to facilitate the practical application of “best practices” for health professionals at the bedside.

The Evolving Road to Market — Opportunities & Risks

Balancing Patient Privacy, Data Security, and Patient Care in the Rapidly Changing Tech and Regulatory Environment: Impact on Seamless Patient Safety
Brian Geisel, CEO, Geisel Software; Peter Madras, MD, President, MDG Boston; and Colin Zick, JD, Partner, Foley Hoag

Moderated by Jeff Karg, CEO, Boston Innovation and Jonathan Bretz, CEO, RSQM

Understanding current trends in HIPAA legislation helps determine how to approach this critical platform type for seamless patient safety. As healthcare information collection becomes easier, data security is essential. Follow expert thinking in utilization of the latest in cybersecurity installations and take away knowledge and important trends to watch for from these experts.

Scanning, 3D Printing, and Smart Materials Technologies: A View into What’s Next —Making Cutting-Edge Technologies Even Better
Sam Onukuri, Sr. Fellow, Johnson & Johnson; Darshana Zaveri, CEO, Lantos Tech; and Daniel Laser, CEO, Applaud Medical

State-of-the-art messages and discussion will highlight this interdisciplinary overview and breakdown of the changes taking place in the market today that are bringing about new patient solutions. Sam Onukuri will lead this session. He is responsible for integrating 3D printing technology across the J&J Enterprise. He and his dedicated team of engineers drive new materials, processes, and software technologies to evolve the business model from what has historically been a product-oriented approach to be a solutions-oriented approach at the point of care. He works closely with J&J leaders in supply chain, R&D, commercial, quality, regulatory, legal, and IT across all segments to execute multiple front-end pipelines of technologies related to 3D printing and netshape technologies. He has over 25 years of experience in medical devices and an extensive background as a metallurgist an in material sciences.


The lunch keynotes will discuss the challenges of funding and driving new emerging medtech to market.

Jeff Burbank, CEO, NxStage Medical

Jeff Burbank is a rare — and extraordinary — business person who has engaged the challenges of funding and driving new emerging medical tech to market. He is the entrepreneur who founded NxStage Medical, in December, 1998. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Today, he remains the principal manager of his company as a multi-million dollar enterprise. He has over 30 years of in-depth management experience with companies developing, marketing, and manufacturing of medical products. During his career, he has been an inventor on over 50 U.S. patents for medical devices. He received his BS in Industrial Engineering from Lehigh University.

Paul Gudonis, CEO, Myomo, Inc.

Many innovators see funding challenges when the cash drawer starts to feel a little light — family and friends are not a viable option, angels are hard to reach, and VCs may be looking to enter after certain milestones. And, on top of that, medical device firms have faced a challenging investment environment for the past few years. It does not seem to be getting any easier; perhaps, harder. Commercial stage, pioneering wearable medical robotics company leader, Paul Gudonis, has addressed these challenges with a unique approach that all fundraising companies hear. He will discuss the company’s decision to go public via the JOBS Act/Regulation A+ process. Myomo was the first company to successfully conduct an IPO under the Reg A+ rules and have its shares listed on a national exchange. He will speak about the timetable, costs, advantages, and disadvantages of using this route to access the capital markets. He will provide insights to other medical device and related life sciences executives considering this process. While this is a little-known approach, since the SEC Regulatory change was initiated in 2015, 60 companies, including Myomo, have now raised $600 million dollars under its provisions.


Specialty Coatings Systems, Booth #204

Specialty Coating Systems is the leader in Parylene conformal coating services and technologies with numerous worldwide locations and 45 years of experience. Ultrathin and pinhole-free, SCS Parylene coatings offer excellent moisture, chemical, and dielectric barrier properties to protect components in the medical device, electronics, military, aerospace, and automotive industries.

New England Wire Technologies, Booth #210

New England Wire Technologies designs and manufactures custom wire and cable products to meet exact specifications or performance characteristics. Manufacturing the most technologically advanced wire and cable in the industry -- Litz wire, ultraflexible single and multi-conductor cables, hybrid cables, braids, and miniature/micro-miniature coaxial cables, NEWT services a variety of industries including medical electronics, robotics and automation, alternative energy, and aerospace/defense. New England Wire Technologies specializes in custom technical cable solutions, short lead times, and unparalleled customer service.